Form 8-K

8-K — VYNE Therapeutics Inc.

Accession: 0001104659-26-084760

Filed: 2026-07-20

Period: 2026-07-16

CIK: 0001566044

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Submission of Matters to a Vote of Security Holders

Documents

8-K — tm2620687d2_8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2620687d2_8k.htm · Sequence: 1

false

0001566044

2026-07-16

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 16, 2026

VYNE

Therapeutics Inc.

(Exact Name of Registrant as Specified in its

Charter)

Delaware

001-38356

45-3757789

(State

or Other Jurisdiction

of Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification No.)

P.O. Box 125, Stewartsville, NJ

08886

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (800) 775-7936

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title

of each class

Trading

symbol

Name

of each exchange

on which registered

Common

Stock, $0.0001 par value

VYNE

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

As previously disclosed, on December 17,

2025, VYNE Therapeutics Inc., a Delaware corporation (“VYNE” or the “Company”), entered into an Agreement and

Plan of Merger and Reorganization (as amended, the “Merger Agreement”), by and among VYNE, Yellow Merger Sub Corp., a Delaware

corporation and a wholly owned subsidiary of VYNE (“Merger Sub”), and Yarrow Bioscience, Inc., a Delaware corporation

(“Yarrow”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,

among other things, Merger Sub will merge with and into Yarrow, with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving

corporation of the merger (the “Merger”).

Item 5.07 Submission of Matters to a Vote of Security Holders.

In connection with the Merger, VYNE held a special

meeting in lieu of the annual meeting of VYNE stockholders on July 16, 2026 (the “Special Meeting”), at which the Company’s

stockholders voted on the proposals set forth below relating to the Merger Agreement. The proposals are described in detail in the Company’s

definitive proxy statement/prospectus filed on Form S-4 with the Securities and Exchange Commission (the “SEC”), most

recently amended on June 3, 2026 and declared effective on June 15, 2026 (as amended, the “Proxy Statement”) and

first mailed to the Company’s stockholders on June 15, 2026. The final voting results regarding each proposal are set forth

below. There were 33,385,055 shares of common stock of VYNE, par value $0.0001 per share (the “VYNE Common Stock”), outstanding

and entitled to vote on June 5, 2026, the record date for the Special Meeting, and 25,949,357 shares of the VYNE Common Stock were

represented in person or by proxy at the Special Meeting, which number constituted a quorum.

Proposal No. 1: To approve the issuance

of shares of VYNE Common Stock (including the shares of VYNE Common Stock issuable upon exercise of VYNE pre-funded warrants) to stockholders

of Yarrow pursuant to the terms of the Merger Agreement, as more fully described in the Proxy Statement , which will (i) represent

more than 20% of the shares of VYNE Common Stock outstanding immediately prior to the Merger under Nasdaq Listing Rule 5635(a) and

(ii) result in a change of control under Nasdaq Listing Rule 5635(b).

Votes For

Votes Against

Abstentions

Broker Non-Votes

15,915,017

137,159

7,840

9,889,341

Proposal No. 2: To approve an amendment

to the amended and restated certificate of incorporation of VYNE (the “VYNE Charter”) to effect a reverse stock split of issued

and outstanding VYNE Common Stock at a ratio determined by the VYNE board of directors and agreed to by Yarrow, of one new share of VYNE

Common Stock for every 10 to 70 shares (or any number in between) of outstanding VYNE Common Stock, in the form attached as Annex C to

the Proxy Statement.

Votes For

Votes Against

Abstentions

25,389,760

550,694

8,903

Proposal No. 3: To approve an amendment

to the VYNE Charter to increase the number of shares of VYNE Common Stock that VYNE is authorized to issue from 150,000,000 to 300,000,000,

in the form attached as Annex D to the Proxy Statement.

Votes For

Votes Against

Abstentions

23,921,348

2,013,526

14,483

Proposal No. 4: To approve

the Yarrow Bioscience, Inc. 2026 Stock Incentive Plan.

Votes For

Votes Against

Abstentions

Broker Non-Votes

12,691,384

3,358,164

10,468

9,889,341

Proposal No. 5: To

approve the Yarrow Bioscience, Inc. 2026 Employee Stock Purchase Plan.

Votes For

Votes Against

Abstentions

Broker Non-Votes

13,131,018

2,909,493

19,505

9,889,341

Proposal No. 6: To elect the

Class II director, Sharon Barbari, to the VYNE board of directors to hold office until VYNE’s 2029 annual meeting of stockholders

and until her successor has been duly elected and qualified, or until her earlier death, resignation or removal; provided that if the

Merger is consummated, the approval of Proposal No. 6 will only have an effect until the completion of the Merger because the composition

of the VYNE board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement.

Votes For

Votes Withheld

Broker Non-Votes

13,507,888

2,552,128

9,889,341

Proposal No. 7: To ratify the appointment

of Baker Tilly US, LLP as VYNE’s independent registered public accounting firm for fiscal year ending December 31, 2026.

Votes For

Votes Against

Abstentions

25,838,022

87,181

24,154

Proposal No. 8: To

approve, on an advisory basis, certain compensation arrangements for VYNE’s named executive officers that are based on or otherwise

relate to the Merger.

Votes For

Votes Against

Abstentions

Broker Non-Votes

15,690,875

247,872

121,269

9,889,341

Proposal No. 9: To approve, on an

advisory basis, the compensation of VYNE’s named executive officers, as disclosed in the Proxy Statement.

Votes For

Votes Against

Abstentions

Broker Non-Votes

15,713,654

245,606

100,756

9,889,341

Proposal No. 10: To approve an adjournment

of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1 and

At the Special Meeting, (i) Proposal Nos. 1, 2, 3, 4, 5, 7, 8

and 9 were approved by the affirmative vote of a majority of the votes properly cast for and against by the holders of VYNE Common Stock

at the Special Meeting and (ii) the Class II director nominee under Proposal No. 6 was elected by the affirmative vote

of a plurality of the votes properly cast by the holders of VYNE Common Stock entitled to vote at the Special Meeting. As there were sufficient

votes to approve Proposal No. 1 and Proposal No. 2 at the time of the Special Meeting, Proposal No. 10 was not presented

to stockholders.

No Offer or Solicitation

This Current Report on Form 8-K is not

intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in

respect of the proposed transactions or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an

invitation to purchase or subscribe for any securities pursuant to the proposed transactions or otherwise, nor shall there be any

sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be

made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.

Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will

not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such

jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission,

telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such

jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION

HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS CURRENT REPORT ON FORM 8-K IS TRUTHFUL OR COMPLETE.

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VYNE THERAPEUTICS INC.

Date: July 17, 2026

/s/ Mutya Harsch

Mutya Harsch

Chief Legal Officer and General Counsel

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Jul. 16, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 16, 2026

Entity File Number

001-38356

Entity Registrant Name

VYNE

Therapeutics Inc.

Entity Central Index Key

0001566044

Entity Tax Identification Number

45-3757789

Entity Incorporation, State or Country Code

Entity Address, Address Line One

P.O. Box 125

Entity Address, City or Town

Stewartsville

Entity Address, State or Province

Entity Address, Postal Zip Code

08886

City Area Code

800

Local Phone Number

775-7936

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

VYNE

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration